These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26685097)

  • 1. Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy.
    Garciaz S; Harel S; Amorim S; Bouabdallah R; Thieblemont C; Brice P
    Br J Haematol; 2016 Nov; 175(4):735-737. PubMed ID: 26685097
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
    Cencini E; Fabbri A; Bocchia M
    Br J Haematol; 2017 Mar; 176(5):831-833. PubMed ID: 26913966
    [No Abstract]   [Full Text] [Related]  

  • 3. Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma.
    Bond DA; Dotson E; Awan FT; Baiocchi RA; Blum KA; Maddocks K
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e123-e128. PubMed ID: 30594446
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage.
    Torka P; Przespolewski E; Evens AM
    JCO Oncol Pract; 2022 Jul; 18(7):491-497. PubMed ID: 35254922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].
    Chen DB; Wang Y; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):635-6. PubMed ID: 21092597
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of lymphocyte-predominant Hodgkin lymphoma.
    Engert A
    Ann Oncol; 2008 Jun; 19 Suppl 4():iv45-6. PubMed ID: 18519402
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.
    Vassilakopoulos TP; Dimopoulou MN; Angelopoulou MK; Petevi K; Pangalis GA; Moschogiannis M; Dimou M; Boutsikas G; Kanellopoulos A; Gainaru G; Plata E; Flevari P; Koutsi K; Papageorgiou L; Telonis V; Tsaftaridis P; Sachanas S; Yiakoumis X; Tsirkinidis P; Viniou NA; Siakantaris MP; Variami E; Kyrtsonis MC; Meletis J; Panayiotidis P; Konstantopoulos K
    Oncologist; 2016 Mar; 21(3):343-53. PubMed ID: 26921291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?
    Canellos GP; Duggan D; Johnson J; Niedzwiecki D
    J Clin Oncol; 2004 Apr; 22(8):1532-3. PubMed ID: 15084636
    [No Abstract]   [Full Text] [Related]  

  • 10. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
    Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study.
    Hutchings M; Radford J; Ansell SM; Illés Á; Sureda A; Connors JM; Sýkorová A; Shibayama H; Abramson JS; Chua NS; Friedberg JW; Kořen J; LaCasce AS; Molina L; Engley G; Fenton K; Jolin H; Liu R; Gautam A; Gallamini A
    Hematol Oncol; 2021 Apr; 39(2):185-195. PubMed ID: 33462822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation in early-stage Hodgkin lymphoma.
    Meyer RM
    Clin Adv Hematol Oncol; 2013 Mar; 11(3):162-89. PubMed ID: 23598983
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Classic Hodgkin's lymphoma in post-treatment hairy cell leukemia: report of a case].
    Chen DB; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):848-9. PubMed ID: 22336215
    [No Abstract]   [Full Text] [Related]  

  • 15. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
    Arakelyan N; Jais JP; Delwail V; Brière J; Moles-Moreau MP; Sénécal D; Berthou C; Desablens B; Colonna P; Andrieu JM;
    Cancer; 2010 Sep; 116(17):4054-62. PubMed ID: 20564152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
    Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
    Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can outcomes be improved for older patients with Hodgkin lymphoma?
    Evens AM; Hong F
    J Clin Oncol; 2013 Apr; 31(12):1502-5. PubMed ID: 23509323
    [No Abstract]   [Full Text] [Related]  

  • 19. Advanced Lymphocyte-rich Classical Hodgkin Lymphoma Complicated with Fatal Hemophagocytic Syndrome.
    Ichikawa S; Takahashi T; Katsushima H; Fukuhara N; Ichinohasama R; Harigae H
    Intern Med; 2016; 55(2):191-6. PubMed ID: 26781022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of lymphoma with respect to pathologic classification: updates and controversies].
    Zhu J; Song YQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):724-7. PubMed ID: 20079009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.